P
Peter M Wilkinson
Researcher at Manchester Royal Infirmary
Publications - 67
Citations - 3066
Peter M Wilkinson is an academic researcher from Manchester Royal Infirmary. The author has contributed to research in topics: Chemotherapy & Pharmacokinetics. The author has an hindex of 25, co-authored 66 publications receiving 3002 citations. Previous affiliations of Peter M Wilkinson include Queen Elizabeth Hospital Birmingham.
Papers
More filters
Journal ArticleDOI
Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial
Ruth Pettengell,Howard Gurney,John Radford,David P Deakin,Roger D James,Peter M Wilkinson,Kevin Kane,Jane Bentley,Derek Crowther +8 more
TL;DR: Overall, patients randomized to receive G-CSF achieved a greater dose intensity than control patients, but this did not result in significant differences in drug toxicity (other than neutropenia), intravenous antibiotic usage, or hospitalization between the two groups.
Journal ArticleDOI
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
A. Clayton,Sarah Danson,S Jolly,W.D.J. Ryder,Paul A Burt,Aengus Stewart,Peter M Wilkinson,R S Welch,B. Magee,G. Wilson,Anthony Howell,Andrew M Wardley +11 more
TL;DR: A high proportion of patients with MBC treated with trastuzumab develop symptomatic cerebral metastases, which indicates that HER-2-positive breast cancer may have a predilection for the brain, or trastzumab therapy may change the disease pattern by prolonging survival.
Journal ArticleDOI
Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker.
TL;DR: Serum CA 125, quantified by an immunoradiometric assay employing the monoclonal antibody 0C125 was found to be elevated in 48/58 (83%) of patients with established ovarian cancer, and the value of CA125 in the management of ovarian malignancy is discussed.
Journal ArticleDOI
Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: Results of a double-blind, randomised trial
John F. Smyth,A Bowman,Timothy J. Perren,Peter M Wilkinson,Robin J Prescott,K. J. Quinn,M Tedeschi +6 more
TL;DR: The results demonstrate that adding GSH to CDDP allows more cycles of CDDP treatment to be administered because less toxicity is observed and the patient's quality of life is improved.
Journal ArticleDOI
Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.
Sophie D. Fosså,Sally P. Stenning,Arthur Gerl,Alan Horwich,Peter I Clark,Peter M Wilkinson,W. G. Jones,Marna Williams,R T D Oliver,Edward S. Newlands,Graham M. Mead,Michael Cullen,Stan B. Kaye,G. J. S. Rustin,P. A. Cook +14 more
TL;DR: Good prognosis parameters are: progression-free interval of > 2 years, CR to induction treatment and normal or low serum markers at relapse and the results of high-dose salvage chemotherapy should be interpreted on the background of these prognostic factors.